Use of antimalarials in dermatology
Identifieur interne : 001659 ( Main/Exploration ); précédent : 001658; suivant : 001660Use of antimalarials in dermatology
Auteurs : Falk R. Ochsendorf [Allemagne]Source :
- JDDG: Journal der Deutschen Dermatologischen Gesellschaft [ 1610-0379 ] ; 2010-10.
English descriptors
- Teeft :
- Abdominal cramps, Academy figure, Academy table, Accommodation disorders, Actual weight, Acute intoxication, Adipose tissue, Adverse effects, Amphiphilic molecules, Amsler grid test, Annual controls, Antigen presentation, Antimalarial, Antimalarial agents, Antimalarial drug therapy, Antimalarial drugs, Antimalarial therapy, Aplastic anemia, Arch dermatol, Author journal compilation blackwell verlag gmbh, Berlin jddg, Berlin jddg academy, Berlin jddg academy table, Berlin jddg jddg, Blackwell, Blood lipids, Body weight, British recommendations, Case reports, Case series, Chloroquine, Chloroquine diphosphate, Clin dermatol, Clinical controls, Clinical improvement, Color vision testing, Combination therapy, Conduction disorders, Control group, Corticosteroid, Cutaneous, Cutaneous lupus, Cutaneous sarcoidosis, Daily dosages, Daily dose, Deep compartments, Dermatol, Dermatomyositis, Dosage, Drug interactions, Erosive lichen planus, Erythematosus, Fewer side effects, G6pd activity, Gleichen teilen, Glucose tolerance, Gmbh, Greater detail, Heavier ones, Heavier patients, Hemolytic effects, Higher dosages, Hydroxychloroquine, Ideal body weight, Ideal weight, Individual basis, Inflammatory diseases, Jddg, Kidney dysfunction, Lichen, Lichen planus, Lighter patients, Liver function, Liver insufficiency, Liver values, Lupus, Lupus erythematosus, Lupus erythematosus tumidus, Lupus flares, Lupus panniculitis, Malaria prophylaxis, Maximum dosage, Maximum effectiveness, Maximum plasma levels, More detail, Necrobiosis lipoidica, Older patients, Ophthalmological examinations, Other diseases, Patient series, Phospholipid antibodies, Planus, Plasma levels, Plasma proteins, Polymorphous light eruption, Poorer response, Porphyria, Porphyria cutanea tarda, Porphyrin excretion, Positive effect, Pregnant women, Protective effect, Psoriasis, Quinacrine, Response rate, Retinopathy, Rheumatoid arthritis, Safe therapy, Sarcoidosis, Semin arthritis rheum, Side effects, Significant reduction, Single dose, Skin diseases, Skin lesions, Skin reactions, Small children, Small number, Standard therapies, Steroid therapy, Syndrome, Synergistic effect, Systematic review, Systemic, Systemic lupus, Systemic lupus erythematosus, Tablet, Tagesdosis liegen, Therapeutic dosages, Therapy, Thrombocyte aggregation, Verlag, Vision field testing, Weight range, Welchem bereich sollte.
Abstract
The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram ideal body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.
Url:
DOI: 10.1111/j.1610-0387.2010.07490.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000024
- to stream Istex, to step Curation: 000024
- to stream Istex, to step Checkpoint: 000604
- to stream Main, to step Merge: 001662
- to stream Main, to step Curation: 001659
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of antimalarials in dermatology</title><author><name sortKey="Ochsendorf, Falk R" sort="Ochsendorf, Falk R" uniqKey="Ochsendorf F" first="Falk R." last="Ochsendorf">Falk R. Ochsendorf</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138A</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1610-0387.2010.07490.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-TF6GR5N0-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000024</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000024</idno><idno type="wicri:Area/Istex/Curation">000024</idno><idno type="wicri:Area/Istex/Checkpoint">000604</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000604</idno><idno type="wicri:doubleKey">1610-0379:2010:Ochsendorf F:use:of:antimalarials</idno><idno type="wicri:Area/Main/Merge">001662</idno><idno type="wicri:Area/Main/Curation">001659</idno><idno type="wicri:Area/Main/Exploration">001659</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Use of antimalarials in dermatology</title><author><name sortKey="Ochsendorf, Falk R" sort="Ochsendorf, Falk R" uniqKey="Ochsendorf F" first="Falk R." last="Ochsendorf">Falk R. Ochsendorf</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Venerology and Allergy University of Frankfurt Hospital, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">JDDG: Journal der Deutschen Dermatologischen Gesellschaft</title><title level="j" type="alt">JDDG JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT</title><idno type="ISSN">1610-0379</idno><idno type="eISSN">1610-0387</idno><imprint><biblScope unit="vol">8</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="829">829</biblScope><biblScope unit="page" to="845">845</biblScope><biblScope unit="page-count">17</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-10">2010-10</date></imprint><idno type="ISSN">1610-0379</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1610-0379</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abdominal cramps</term><term>Academy figure</term><term>Academy table</term><term>Accommodation disorders</term><term>Actual weight</term><term>Acute intoxication</term><term>Adipose tissue</term><term>Adverse effects</term><term>Amphiphilic molecules</term><term>Amsler grid test</term><term>Annual controls</term><term>Antigen presentation</term><term>Antimalarial</term><term>Antimalarial agents</term><term>Antimalarial drug therapy</term><term>Antimalarial drugs</term><term>Antimalarial therapy</term><term>Aplastic anemia</term><term>Arch dermatol</term><term>Author journal compilation blackwell verlag gmbh</term><term>Berlin jddg</term><term>Berlin jddg academy</term><term>Berlin jddg academy table</term><term>Berlin jddg jddg</term><term>Blackwell</term><term>Blood lipids</term><term>Body weight</term><term>British recommendations</term><term>Case reports</term><term>Case series</term><term>Chloroquine</term><term>Chloroquine diphosphate</term><term>Clin dermatol</term><term>Clinical controls</term><term>Clinical improvement</term><term>Color vision testing</term><term>Combination therapy</term><term>Conduction disorders</term><term>Control group</term><term>Corticosteroid</term><term>Cutaneous</term><term>Cutaneous lupus</term><term>Cutaneous sarcoidosis</term><term>Daily dosages</term><term>Daily dose</term><term>Deep compartments</term><term>Dermatol</term><term>Dermatomyositis</term><term>Dosage</term><term>Drug interactions</term><term>Erosive lichen planus</term><term>Erythematosus</term><term>Fewer side effects</term><term>G6pd activity</term><term>Gleichen teilen</term><term>Glucose tolerance</term><term>Gmbh</term><term>Greater detail</term><term>Heavier ones</term><term>Heavier patients</term><term>Hemolytic effects</term><term>Higher dosages</term><term>Hydroxychloroquine</term><term>Ideal body weight</term><term>Ideal weight</term><term>Individual basis</term><term>Inflammatory diseases</term><term>Jddg</term><term>Kidney dysfunction</term><term>Lichen</term><term>Lichen planus</term><term>Lighter patients</term><term>Liver function</term><term>Liver insufficiency</term><term>Liver values</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus erythematosus tumidus</term><term>Lupus flares</term><term>Lupus panniculitis</term><term>Malaria prophylaxis</term><term>Maximum dosage</term><term>Maximum effectiveness</term><term>Maximum plasma levels</term><term>More detail</term><term>Necrobiosis lipoidica</term><term>Older patients</term><term>Ophthalmological examinations</term><term>Other diseases</term><term>Patient series</term><term>Phospholipid antibodies</term><term>Planus</term><term>Plasma levels</term><term>Plasma proteins</term><term>Polymorphous light eruption</term><term>Poorer response</term><term>Porphyria</term><term>Porphyria cutanea tarda</term><term>Porphyrin excretion</term><term>Positive effect</term><term>Pregnant women</term><term>Protective effect</term><term>Psoriasis</term><term>Quinacrine</term><term>Response rate</term><term>Retinopathy</term><term>Rheumatoid arthritis</term><term>Safe therapy</term><term>Sarcoidosis</term><term>Semin arthritis rheum</term><term>Side effects</term><term>Significant reduction</term><term>Single dose</term><term>Skin diseases</term><term>Skin lesions</term><term>Skin reactions</term><term>Small children</term><term>Small number</term><term>Standard therapies</term><term>Steroid therapy</term><term>Syndrome</term><term>Synergistic effect</term><term>Systematic review</term><term>Systemic</term><term>Systemic lupus</term><term>Systemic lupus erythematosus</term><term>Tablet</term><term>Tagesdosis liegen</term><term>Therapeutic dosages</term><term>Therapy</term><term>Thrombocyte aggregation</term><term>Verlag</term><term>Vision field testing</term><term>Weight range</term><term>Welchem bereich sollte</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The antimalarials chloroquine and hydroxychloroquine have been used for the treatment of inflammatory diseases for more than 60 years. Even today new indications evolve due to the complex mode of action of these compounds. Due to the fear of side effects, especially irreversible retinopathy, their use is often limited. These side‐effects, however, are a consequence of excessive daily dosages. An effective, safe therapy needs correct dosing, i. e. adherence to maximal daily dosages of 3.5(–4) mg chloroquine or 6(–6.5) mg hydroxychloroquine per kilogram ideal body weight. If the actual body weight is lower than the ideal body weight, this actual weight is used for the calculation of the dosage. Observing these limits allows a rather safe therapy of the diseases like lupus erythematosus, REM syndrome, porphyria cutanea tarda (2 × 125 mg chloroquine/week), cutaneous sarcoidosis and dermatomyositis. If standard therapies fail, then antimalarials can be tried to treat Sjögren syndrome, granu‐loma annulare or erosive lichen planus. If therapy fails, either can be combined with quinacrine to increase their effectiveness. Chloroquine and hydroxychloroquine are indispensable and well‐tolerated essential drugs in dermatology and especially suited as part of a combination scheme, for example with corticosteroids, as they act synergistically and reduce side‐effects.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li></region><settlement><li>Francfort-sur-le-Main</li></settlement></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Ochsendorf, Falk R" sort="Ochsendorf, Falk R" uniqKey="Ochsendorf F" first="Falk R." last="Ochsendorf">Falk R. Ochsendorf</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001659 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001659 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1ACD6990A65BC9A46D23B9C0A5BDDCBCDF0B138A
|texte= Use of antimalarials in dermatology
}}
| This area was generated with Dilib version V0.6.33. |  |